24/7 Market News Snapshot 27 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)

August 27, 2025

DENVER, Colo., 27 August, 2025 (www.247marketnews.com) – (NASDAQ:BTAI) are discussed in this article.
BioXcel Therapeutics, Inc. (BTAI) is experiencing a notable surge in stock value, currently trading at $6.356, reflecting a significant increase of 21.3% from the previous closing price of $5.240. The heightened trading volume of approximately 3.28 million shares indicates strong market enthusiasm, potentially driven by recent positive developments within the company. This upward trend suggests robust investor confidence, particularly as BTAI breaks through crucial resistance levels, which may signal further bullish momentum in the near future.

A pivotal catalyst for this surge is BioXcel’s announcement regarding the successful completion of the SERENITY At-Home Pivotal Phase 3 trial. This trial evaluated the efficacy of BXCL501, a sublingual film formulation of dexmedetomidine, for treating agitation associated with bipolar disorders and schizophrenia in an at-home setting. The trial met its primary endpoint, demonstrating that BXCL501 was well-tolerated by patients; results showed a substantial proportion of participants experienced symptom resolution during over 2,400 recorded agitation episodes. Notably, the medication exhibited consistent tolerability across repeated dosing without serious adverse events, emphasizing its potential viability for outpatient use.

Dr. Vimal Mehta, CEO of BioXcel Therapeutics, expressed enthusiasm over the trial’s results, highlighting that BXCL501 addresses a significant unmet medical need by offering a treatment option for agitation episodes outside of medical supervision—an area currently lacking FDA-approved therapies. With plans for a supplemental New Drug Application (sNDA) submission in early 2026, the company is poised to tap into a substantial market opportunity, aiming to address millions of agitation episodes annually.

BioXcel is committed to advancing BXCL501 as a transformative treatment in mental health care while leveraging artificial intelligence to innovate within the neuroscience therapeutic landscape. The company is preparing to hold a conference call to discuss the trial’s promising results and outline future strategic directions.

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.